Supplementary Figure 1. Patient Disposition.

Screened
N=564

Enrolled
n=468 (83.0%)

Randomized to onabotulinumtoxinA (n=233)
Discontinued, n=10
- Adverse events, n=4
- Lost to follow-up, n=1
- Personal reasons, n=2
- Protocol violation, n=1
- Other, n=2
Completed double-blind phase (n=223)

Randomized to placebo (n=235)
Discontinued, n=8
- Adverse events, n=2
- Personal reasons, n=3
- Protocol violation, n=1
- Other, n=2
Completed double-blind phase (n=227)